Iranian Among Top World Scientists

Saturday, February 22, 2014

Compiled By: Firouzeh Mirrazavi
Deputy Editor of Iran Review

*Iranian among top world scientists

The latest ranking of Web of Knowledge, which is based on articles written by scientists, shows Professor Hossein Najmabadi is among the top 1 percent of world scientists.

Najmabadi is a medical scientist at the University of Social Welfare and Rehabilitation Sciences (USWR) and founder of Genetics Research Center (GRC), Mehr News Agency reported.  

He is known for his significant contribution to the genetics of mental retardation.

The Iranian scientist studied biology at the University of North Texas and received a PhD in molecular biology from the same university in 1989. He then joined UCLA as a postdoc and was appointed a faculty member of Charles Drew University of Medicine & Science-UCLA in 1995.

Najmabadi has published more than 100 peer-reviewed papers in international journals in the field of medical genetics and cancer genetics.

His recent studies were focused on preventing genetic disabilities and disorders through the establishment of a nationwide strategy for the early prenatal diagnosis of genetic disorders. In five areas of preventable genetic disorders, Najmabadi leads projects that not only apply preventive solutions within the population, but also involve nationally and internationally collaborative research to improve the quality of life nationwide.

*Iranian Researcher Creates artificially linked DNA

An interdisciplinary study led by Dr Ali Tavassoli, a Reader in chemical biology at the University of Southampton, has shown for the first time that 'click chemistry' can be used to assemble DNA that is functional in human cells, which paves the way for a purely chemical method for gene synthesis.

Writing in Angewandte Chemie International Edition Dr Tavassoli's team and his collaborators, Dr Jeremy Blaydes and Professor Tom Brown, show that human cells can still read through strands of DNA correctly despite being stitched together using a linker not found in nature.

The artificially linked DNA was created by joining oligonucleotides using click chemistry -- chemistry tailored to mimic nature which generates substances quickly and reliably by joining small units together.

This click technique is highly efficient and boasts a number of advantages over the usual approaches to assembling DNA strands in the lab using a combination of DNA synthesis, PCR amplification and enzymatic ligation.

"As chemists we always sought to synthesise long strands of DNA but have been limited by our assumption that the phosphodiester bond is necessary for DNA to function in cells," says Dr Tavassoli. The DNA backbone is made up of pentose sugars and phosphate groups that stitch the nucleotides together using phosphodiester bonds. This backbone acts as the scaffold for the four bases that make up the genetic code.

The click DNA approach relies on a rapid and efficient stitching together of modified DNA strands using the copper-catalysed alkyne-azide cycloaddition reaction. Click-linking DNA leaves behind a triazole group in the backbone and it was feared that cellular machinery would be unable to read these unnaturally joined DNA strands. The new study demonstrated error-free transcription in human cells, the first example of a non-natural DNA linker working correctly in eukaryotic cells.

"This is important because it shows that we don't have to stick to the phosphodiester backbone of the DNA at the site of DNA ligation," Dr Tavassoli explains. "This suggests that we can replace the enzymatic methods for DNA assembly and DNA ligation with highly efficient chemical reactions."

"This is a mind blowing advance that demonstrates chemistry's power to manipulate nature's nature," comments Nobel laureate Barry Sharpless at the Scripps Research Institute, US, who first described the click chemistry process. "I only dreamed I'd get to see click chemistry do this in my lifetime. It is a marvellous achievement."

*Iranian helps cultivate synthetic stem cells

Scientists at the University of California and British Surrey University along with an Iranian researcher Azin Fahimi have developed a new method to cultivate stem cells that does not originate from human and animal cells.

Earlier, stem cells have been cultivated using animal proteins or by growing them from other human cells, ISNA reported.

Both methods come with associated problems. But, according to a study published in the journal Applied Materials & Interfaces, researchers have now identified a new method for cultivating stem cells.

Stem cells are able to divide or regenerate indefinitely. This allows the stem cells to generate into a range of cell types for the organ that they originate from, or they may even be able to regenerate the whole organ.

Because of this, scientists are interested in using stem cells in a range of medical treatments, to replenish damaged tissue in the brain or skin, or as a treatment for blood diseases.

In adults, these stem cells have been found in tissues such as the brain, bone marrow, blood, blood vessels, skeletal muscles, skin and liver. Adult stem cells only become ‘activated’ and start dividing and generating new cells when their host tissue becomes damaged by disease or injury.

A more potent kind of stem cell is found in human embryos, which has the unique ability to grow into any kind of cell in the human body. But using these cells in scientific research is controversial—and illegal in some countries—as harvesting them requires the destruction of a fertilized human egg (a ‘blastocyst’) that has not had the chance to develop into a baby.

Stem cells can be grown in laboratories using animal proteins, but these cannot be used in the treatment of humans. An alternative method of growing stem cells on other human cells is risky, as the cells could be contaminated and may transmit disease to the patient.

Now, Prof. Peter Donovan from the University of California and a team of scientists at the University of Surrey in the UK have developed a new method for cultivating stem cells, which involves using carbon ‘nanotubes’ as a ‘scaffold’ from which human stem cells can be grown. The new synthetic cell structure allows stem cells effective in humans to be grown safely in the laboratory.

Dr. Alan Dalton, senior lecturer from the Department of Physics at the University of Surrey, said, “While carbon nanotubes have been used in the field of biomedicine for some time, their use in human stem cell research has not previously been explored successfully.”

This scaffolding imitates the supporting cells in the human body that stem cells would have been grown on. The creation of this synthetic cell structure now allows stem cells effective in humans to be grown safely in the laboratory.

The researchers think that this new development will open doors to “revolutionary steps” in replacing tissue after injury or disease.

Dr. Dalton said, “Synthetic stem cell scaffolding has the potential to change the lives of thousands of people suffering from diseases such as Parkinson’s, diabetes and heart disease, as well as vision and hearing loss. It could lead to cheaper transplant treatments and could potentially one day allow us to produce whole human organs without the need for donors.”

Recently, Medical News Today reported on a study finding that stem cells could be harvested from tissue discarded in routine hip replacement operations.

*Iranian scientists discover a rare bacterium

Researchers in Iran Biological Resource Center have discovered a new bacterium, publish in International Systematic Microbiology Journal.

Actinomycetes are valuable microorganisms used for the 1st and 2nd metabolism in food industries. These microorganisms help produce enzymes widely applied in food industry to process starch in fructose-rich drinks and enzymes used in molecular biology techniques.

Actinomycetes are also applied in production of new generations of antibiotics due to their specific metabolism routes.

Researchers in Iran Biological Resources Center discovered a rare actinomycete belonging to the family Pseudonocardiaceae. The discovery of this microorganism was announced in a paper in the prestigious IJSEM under the name of Alloactinosynnema Iranicum

The microorganism is accessible in National Iranian Biological Resource Center as a valuable microorganism in access code of BRC-M 10403T.

*Iranian anticancer drug produced

The first Iranian biosimilar anticancer drug was unveiled at an official ceremony attended by the head of Iran’s Food and Drug Organization, announced the director general of Cinnagen Company.

Dr. Haleh Hamedi-Far said Cinnagen Company is the first company in the country and the second in the world to produce such anticancer drug, Fars News Agency reported.

She added that the drug, by the name of ‘Pegagen’, has successfully passed all animal and human tests and obtained legal permits for mass production.

“Pegagen is a biosimilar anticancer drug which can be used to treat all types of cancer after chemotherapy,” she noted. “Its most important advantages are high efficiency and reduced need for injection.”

Hamedi-Far also disclosed that a contract will be signed on the sidelines of the ceremony between an Iranian drug company and a Turkish company to transfer the knowledge and technology of producing MS-related drug (Resigen), adding that it is the first time that Iran is sharing its drug production know-how with another country.

She said that the Turkish party will produce the drug under license from the Iranian company.

Rasoul Dinarvand, the head of Iran’s Food and Drug Organization announced last week that an Iranian drug company has succeeded in producing the first Iranian anticancer monoclonal antibody drug which is to be unveiled soon.

He said that the production process of monoclonal antibody drugs are much complicated and this makes them expensive.

He added that once monoclonal antibody drugs are produced domestically, the prices will come down.

The head of Iran’s Food and Drug Organization hoped that at least six types of monoclonal antibody drugs can be produced in the next two years once the production line for monoclonal antibody drugs is set up in the country.

Monoclonal antibody drugs are a relatively new innovation in cancer treatment. A monoclonal antibody is a laboratory-produced molecule that’s carefully engineered to attach to specific defects in your cancer cells.

Monoclonal antibodies mimic the antibodies your body naturally produces as part of your immune system’s response to germs, vaccines and other invaders.

Monoclonal antibodies are designed to recognize and attach to specific proteins on the surface of cells. Each monoclonal antibody recognizes one particular protein.

They work in different ways depending on the protein they are targeting. So monoclonal antibodies have to be made to target different types of cancer.

Many different monoclonal antibodies are already available to treat cancer. Some are licensed to treat particular types of cancer while newer types are still undergoing clinical tests. Monoclonal antibodies cause different side effects. It can take a long time to develop this type of treatment because making monoclonal antibodies can be very complicated.

*Iranian researcher's method shows how brain recognizes speech sounds

Researchers at the University of California San Francisco along with an Iranian scientist Nima Mesgaran showed in a new study - published in the journal Science - that the shaping of sound by our mouths leaves "an acoustic trail" that the brain follows.

Scientists have known for some time that it is the superior temporal gyrus (STG; also known as "Wernike's area") where speech sounds are interpreted. But not much has been known about how the brain actually processes speech.

To investigate this, the University of California San Francisco (UCSF) researchers placed neural recording devices directly onto the surface of the brains of six patients who were undergoing epilepsy surgery. This allowed the researchers to capture very rapid changes in the brain.

This was one of the most advanced studies of the brain's interpretation of speech. Previous studies had only been able to analyze neural responses to just a handful of natural or synthesized speech sounds, but because of the speed of the technology used by the UCSF team, they were able to use every kind of speech sound in the English language, multiple times.

The researchers collected data from the STGs of the patients as they listened to 500 unique English sentences spoken by 400 different people.

What the researchers expected was to see the patients' brains respond to "phonemes." Phonemes are the individual sound segments that make up language - the researchers give the example of the b sound in "boy."

Instead, the researchers found that the brain was "tuned" to an even simpler function of language - something linguists call "features." Features are distinctive "acoustic signatures" that the human body makes when we move our lips, tongue or vocal cords, Medicalnewstoday reported.

One type of feature are called "plosives" - these occur when, to make a certain speech sound, the speaker has to use the lips or tongue to obstruct air flowing from their lungs, causing a brief burst of air. Examples of plosives are the consonants p, t, k, b and d.

Another type of feature are "fricatives" - these sounds are when the airway is only partially obstructed, which causes friction in the vocal tract. S, z and v are examples of fricatives.

Analyzing the data from the patients' brains, the researchers saw the STGs of the patients "light up" as the participants heard the different speech features. The team found that the brain recognized the "turbulence" created by a fricative, or the "acoustic pattern" of a plosive, rather than individual phonemes such as b or z.

The researchers compare this system for interpreting the "shapes" of sounds to the way the brain recognizes visual objects using edges and shapes. The visual system allows us to identify known objects regardless of the perspective from which we are viewing them, so the researchers think it makes sense that the brain would apply a similar algorithm to understanding sound.

The study's senior author, Dr. Edward F. Chang, said, "It's the conjunctions of responses in combination that give you the higher idea of a phoneme as a complete object. By studying all of the speech sounds in English, we found that the brain has a systematic organization for basic sound feature units, kind of like elements in the periodic table."

The UCSF team hopes their findings will contribute to work around reading disorders. In a reading disorder, printed words are inaccurately mapped by the brain onto speech sounds.

But the team thinks that the findings are significant in their own right. "This is a very intriguing glimpse into speech processing," Chang says. "The brain regions where speech is processed in the brain had been identified, but no one has really known how that processing happens."

Recently, Medical News Today reported on a study that found speech uses both sides of the brain - previously scientists thought just one half of the brain was used for speech and language.

*University of Zanjan among top academies

University of Zanjan has been selected among top academies in UI Greenmetric World University Ranking.

The university was ranked 128 with a score of 5,225, IRNA reported.

Universitas Indonesia (UI) releases the results of UI GreenMetric ranking annually.

This is the fourth year of this ranking, which compares academic efforts toward campus sustainability and environment-friendly university management.

The results were announced by Prof. Muhamad Anis and UI Greenmetric Chairman Prof. Riri Fitri Sari, accompanied by Prof. Gunawan Tjahjono and Dr. Nyoman Suwartha, at Central Administration Building of UI, Depok, Indonesia.

This year, 301 universities from 61 countries took part, which is an increase from last year with 215 universities from 49 countries.

University of Nottingham (UK) was ranked first with a score of 7,521, followed by University College Cork National University of Ireland (score 7,328) and Northeastern University of USA at third position with a score of 7,170.

Apart from USA, Japan, britain and other European countries that have participated in last year’s ranking, the 2013 results include universities from Iran, Morocco, Egypt, Namibia, Cyprus, Slovenia, Estonia, Ukraine, Portugal, Philippines, Jordan, Panama and Pakistan.

The results are computed from information provided by universities online. This year, the information is organized under six categories. These categories are setting and infrastructure, energy and climate change, waste management, water usage, transportation and education.

This initiative was launched on 2010 to draw the attention of university leaders and stakeholders to pay more attention to environmental sustainability, as well as economic and social problems related to sustainability.

*Iran third in HSCT

Iran ranks third in hematopoietic stem cell transplantation (HSCT) in the world, announced the head of Shariati Hospital’s Hematology-Oncology Research Center and Stem Cell Transplantation.

Dr. Ardeshir Qavamzadeh added Shariati Hospital handles about 400 cases of hematopoietic stem cell transplantation annually, IRNA reported.

The HSCT is the transplantation of multipotent hematopoietic stem cells, usually derived from bone marrow, peripheral blood or umbilical cord blood. It is a medical procedure in the fields of Hematology, most often performed for patients with certain cancers of the blood or bone marrow, such as multiple myeloma or leukemia. In these cases, the recipient’s immune system is usually destroyed with radiation or chemotherapy prior to transplantation.

He noted that cancer can be treated if it is diagnosed in the early stages.

Iranian hematologic specialist said there is no need for all features of donor’s stem cells to be compatible with those of the recipient, adding that the operation can be carried out with just 50 percent compatibility.

“Our stem cell specialists are among the best in the world providing medical services to both children and adults,” Qavamzadeh said.

Eight stem cell centers have been established in a number of cities including Shiraz, Kerman, Mashhad and Orumieh in cooperation with Hematology-Oncology Research Center and Stem Cell Transplantation of Shariati Hospital, he added.

“There are about 200 stem cell specialists nationwide and none of the provinces lack stem cell-related medical services,” he noted.

The Hematology-Oncology Research Center and Stem Cell Transplantation is affiliated to Tehran University of Medical Sciences and based in Shariati Hospital, Tehran, Iran. As a main national hematology-oncology center, it is among the most prominent stem cell transplantation centers in the world, with more than 400 successful transplantations performed per year.

The Center is mainly involved in new therapeutic approaches which are developed or under development for hematologic-oncologic patients, particularly stem cell transplantation. In addition, it is involved in the research activities to improve the diagnosis and management of different hematologic and oncologic diseases.

The Center was founded in 1991 by Ardeshir Ghavamzadeh, who is currently its director.

*Hepatoblastoma treatment by stem cell injections in Iran

Doctors and specialists of the Mahak Hospital announced that for the 1st time in Iran, the 1st child recovered from hepatoblastoma left the hospital healthfully.

Hepatoblastoma is the most common form of liver cancer in children, although it is a comparatively uncommon pediatric solid tumor. The disease usually affects children younger than 3 years.

Arian is the 22nd child suffering from hepatoblastoma in the world, and the 1st one in Iran, being successfully treated by stem cell injections.

The Mahak Society to Support Children with Cancer is an organization in Tehran dedicated to helping Iranian children with cancer.

MAHAK’s Hospital and Rehabilitation center equipped to accommodate up to 120 children, each accompanied by a member of their family. The center houses diagnostic and treatment wards of the highest standards, on a par with those seen anywhere else.

Iran is the 4th country, after US, Italy and Japan, which has been successful to treat hepatoblastoma in the world. 

*Iranians help achieve early diagnosis of prostate cancer

Iranian researchers have developed a new nanoprobe to diagnose cancerous cells, in association with their Australian and Belgian counterparts.

The main characteristic of the nanoprobe is to diagnose the disease before it causes physiological changes in the body, Fars News Agency reported.

Among the applicable medical properties of the results of this research, mention can be made of imaging, separation of cancerous cells from healthy ones, hyperthermia and determination of gene expression.

Taking into account the advantages and wide applications of MRI in different cancer treatment stages, the need for paying attention to new imaging methods is increasing day by day to converge and improve the sensitivity of imaging method, especially magnetic resonance molecular imaging (MRMI).

In this research, a magnetic nanoprobe was designed and tested to increase the sensitivity of MRI method to detect prostate cancer cells.

In this research, PSMA antigen, which is a specific antigen for prostate cancer with high expression on the surface of cancerous cells but with no expression on the surface of prostate natural cells, was determined as an ideal target agent. Next, J591 antibody was chosen as targeting agent due to its unique properties.

The antibody was attached to the magnetic iron nanoparticle with a coating of polyethylene glycol and –NH2 surfactants after activation and preparation of particles by using a specific cross-linker entitled Sulfo-SMCC. After the production of nanoprobe, its physical and chemical properties and performance were investigated in in-vitro and in-vivo applications.

The difference in this research with similar researches is in introducing and developing the contrast agent that is able to detect prostate cancer cells among the healthy ones, which can result in early diagnosis of the disease before it causes physiological changes in cells.

*Iran ranks 18th in world in medical sciences

The Islamic Republic of Iran has ranked 18th in terms of science production in medicine in the world, according to the latest statistics released by several international scientific centers.

Iran has garnered this high ranking from among 238 countries across the world, IRNA quoted the deputy manager of education at Iran’s Health Ministry Amir Mohsen Ziaei as saying.

In 2000, the Islamic Republic ranked 53rd in the world in terms of highly cited medical articles but improved to the 23rd rank in 2011.

Iran has taken wide strides in science and technology in recent years despite US sanctions.

Iran also ranked 20th in science production in the world in 2013, according to the recent statistics announced by Thomson Reuters.

Iran has allocated 1.57 % of the world science production since the beginning of 2013 that located the country in the released rank by Thomson Reuters.

Meanwhile, Iran has also ranked first in the region and eighth in the world in science production in the field of nanotechnology, the secretary of Iran Nanotechnology Initiative Council (INIC) Saeed Sarkar had earlier announced.

Iran's 2009 growth rate in science and technology was highest globally being 11 times faster than the world's average rate.

*Iranian researchers develop new methods in gastronomical cancers

Researchers in the Mashhad University of Medical Sciences Center for Genetic Research has developed a new method for treating gastrointestinal cancers.

Dr. Mohammad Reza Abbaszadegan, the project senior researcher told Mehr News that the research was carried out on factors contributing to esophagus cancer. “The method works through molecular interventions of the factors,” he said. “We examined two factors of somatic cells (specifically esophagus epithelial cells), which would turn into fundamental malignant tumors,” he added, “The study was carried out on a sample population of patients diagnosed with esophagus cancer.”

“We found that a high percent of patients had the factor, including Mastermind and Twist 1 factors,” he said. “The second phase of the research would examine whether this method would stop the growth of cancer cells, where we found some success,” said the senior researcher.

The head of Mashhad University of Medical Sciences Center for Genetic Research also pointed to the side-effects of non-specific treatment such as chemotherapy and radiotherapy. “General strands of treatment have side-effects on patients, while the preset method is a specifically biological method,” he said.

“The research findings would find applications in the treatment of larger intestine cancers,” he added.

*Iranian researcher conquests Everest of cancer genes

The ‘Everest’ of cancer genes has been conquered by an Iranian scientist at California university.

Kevan Shokat along with his colleagues have found a way to shut off a gene that causes a third of all tumours, including some of the most deadly.

Despite advances in medicine, cancer kills more than 150,000 Britons a year – the equivalent of a life every four minutes.

The breakthrough could lead to new drugs for hard-to-treat cancers. As well as saving lives, the new treatments should have fewer side-effects than existing medicines.

The excitement surrounds a gene called ras, which when mutated can trigger the development of tumours, fuel their growth and keep them alive.

A drug that shuts it down has eluded some of the best brains in science for more than 30 years, leading many to believe it was unbeatable.

Now, US scientists have succeeded in making a chemical that kills ras-driven human lung cancer cells.

Researcher Kevan Shokat, of the Howard Hughes Medical Institute at the University of California, described the rogue gene as ‘the Everest of cancer mutations’.

He said: ‘People have tried to drug every part of ras and looked at every nook and cranny on it and screened a million compounds and never found anything that inhibits it well.

‘We are very excited. We believe this has real implications for patients.’ Cancers caused by the ras gene are particularly fast growing and spreading and difficult to treat.

'They include many pancreatic, lung and bowel cancers, which between them kill almost 60,000 Britons a year.

Pancreatic cancer is the most deadly common cancer, with fewer than 20 per cent of patients alive a year after diagnosis and under 4 per cent surviving for five years.

Lung cancer kills more Britons than any other form of the disease, with almost 35,000 deaths a year. Bowel cancer is the second biggest cancer killer, with around 16,000 deaths annually.

It is hoped that by shutting off ras, the new drug will stop the growth of tumours and shrink them.

Crucially, it acts only on the cancer-causing form of the ras gene, meaning healthy cells are spared. This should cut the risk of side-effects such as sickness, nausea and hair loss normally seen with cancer drugs.

Dr. Shokat, who has formed a company to commercialise his work, said: ‘What is very special about this drug is that it only works in cells that have this particular mutation. That distinguishes it from every other cancer drug we know of.’

*Iranian university professor receives ASME fellowship

An Iranian civil engineer university professor Hossein Mohammadi Shoja at Sharif University was introduced as a Fellow member of the US ASME because of his valuable international research projects.

Over 130,000 people from 158 countries have so far joined the ASME, but only 3,000 people across the world have managed to get fellowship, the highest degree in the association's membership.

The Association for the Study of Medical Education (ASME) was founded in 1880 to provide a setting for engineers to discuss the concerns brought by the rise of industrialization and mechanization. The Society’s founders were some of the more prominent machine builders and technical innovators of the late nineteenth century; led by prominent steel engineer Alexander Lyman Holley, Henry Rossiter Worthington and John Edison Sweet.

Ali Meghdari, another Iranian university professor of mechanical engineering of Sharif University has already received fellowship from the ASME.

*Iranian ophthalmologists treat cataract, transplant corneal by new laser-therapy

Iranian researchers have managed to treat cataract by a new laser-therapy method using femtoSecend laser system.

"Using the new device which is the newest and the most precise one in the world, we are now capable of operating different types of congenital cataracts made due to impacts in the country," said an Iranian ophthalmologist Mostafa Naderi.

The device can make delicate and precise cuts to treat other types of eye diseases such as presbyopia, keratoconus and removing astigmatism and corneal transplants.

All people suffering congenital cataracts and even the elderly can use the method which has the least possibility of human error in the treatment process.

FemtoSecend laser system does not hurt surrounding tissues, especially cornea, boosts eye resistance against possible impacts and shortens the period of patient convalescent.

*Iran’s Razi medical research festival honors winners

Iran’s 19th National Razi Research Festival on medical sciences has honored its winners during a ceremony held in the capital city of Tehran, Press TV has reported.

Iranian President Hassan Rouhani, the vice-president for Research and Technology and the Health Ministry officials attended the ceremony held in Tehran’s Shahid Beheshti University on January 15.

Winners were selected from among researchers of different Iranian universities and awarded in different categories including medical nanotechnology, psychology and psychiatry, pharmaceutical sciences and dentistry.

Razi Medical Sciences Research Festival was founded in 1995 after the name of the great Iranian physician, chemist, pharmacist, and philosopher, Razi who lived in the 9th century CE.

The festival is annually held to encourage innovation and research in medical sciences.

Iran has taken wide strides in science and technology in recent years despite US sanctions.

Iran has ranked 18th in terms of science production in medicine in the world, according to the latest statistics released by several international scientific centers.

Iran has garnered this high ranking from among 238 countries across the world.

The country has also ranked first in the region and eighth in the world in science production in the field of nanotechnology, the secretary of Iran Nanotechnology Initiative Council (INIC) Saeed Sarkar had earlier announced.

Iran is now exporting its nanotechnology products to around ten countries including Australia, Turkey, Pakistan and Malaysia, he also noted.

*Iranian researchers regenerate kidney using stem cells

Researchers in Royan Institute has regenerated kidney tissues of monkey using stem cells.

Dr. Reza Moghaddasali told Mehr News that they selected cellular therapy of acute and chronic diseases in animal media with good results. He also expressed hope that a day would come when the results of the study would be used for human kidney disorders.

He cited hypertension and diabetes as factors of kidney disorders. “The most common treatment is transplant, which according to global data, 20 per cent of patients develop inflammatory reaction to the transplanted organ. Thus, we have in the agenda to regenerated the failing tissues of kidney,” the project manager said.

“We regenerated failed kidney tissues in monkeys using Cisplatin chemotherapeutic drug, and then we injected stem cells to failed tissues, which improved their function,” he added.

Moghaddasali cited decreased Natrium and urea as symptomatic of improved kidney function in animal media. “We are planning to use these cells in human media,” he said, pointing to other Royan Institute other research projects. “In engineering of kidney tissues, we are working to develop a connective tissue using kidney tissues,” he added, expressing hope that in coming years he would use these findings clinically.